Brief: Ultimovacs Q3 Loss For The Period Widens To NOK 17.2 Million

Zelluna ASA

14/11/2019 07:21

Nov 14 (Reuters) - Ultimovacs ASA  ULTIMO.OL :
    * Q3 LOSS FOR THE PERIOD NOK 17.2 MILLION VERSUS LOSS NOK
16.9
MILLION YEAR AGO
    * Q3 NEGATIVE CASH FLOW FROM OPERATIONS WAS NOK 18.3 MILLION
    * IN PHASE I STUDY IN MALIGNANT MELANOMA WHERE UV1 IS
COMBINED
WITH PEMBROLIZUMAB (PD1 INHIBITOR), NUMBER OF PATIENTS HAS BEEN
INCREASED FROM 20 TO 30
    * AIMS TO HAVE ALL PATIENTS IN PHASE I STUDY IN MALIGNANT
MELANOMA
RECRUITED DURING Q1-20, AND ALL SAFETY DATA AVAILABLE SHORTLY
THEREAFTER
    * IS PREPARING A RANDOMIZED PHASE II TRIAL WHERE UV1 WILL BE
COMBINED WITH ANTI-PD-1 PLUS ANTI-CTLA-4 IN METASTATIC MALIGNANT
MELANOMA
    * RANDOMIZED PHASE II TRIAL INTENDED TO BE INITIATED IN
Q1-20,
WITH READOUT OF PRIMARY ENDPOINT PROGRESSION-FREE SURVIVAL (PFS)
DURING SECOND HALF OF 2022
    * HAS ONGOING DISCUSSIONS TO ENTER INTO COOPERATION PROJECTS
WITH
ACADEMIC INSTITUTIONS AND PHARMACEUTICAL COMPANIES IN ORDER TO
DOCUMENT EFFECT AND SAFETY OF UV1 IN OTHER CANCER TYPES AND IN
COMBINATIONS WITH DIFFERENT CANCER TREATMENTS
    * RESEARCH AND DEVELOPMENT ACTIVITIES CURRENTLY FOCUSED ON
DEVELOPMENT OF NEW FIRST-IN-CLASS CANCER VACCINE SOLUTION
BUILDING ON TECHNOLOGY OF ULTIMOVACS AND THE ACQUIRED
TET-PLATFORM, AND ON DEVELOPMENT OF NEW MOLECULES AND
TECHNOLOGIES BASED ON BIOBANK MATERIAL FROM THE ONGOING AND
PLANNED CLINICAL STUDIES CONDUCTED WITH UV1

Source text for Eikon:  ID:nObiPyMzra 
Further company coverage:  ULTIMO.OL 

 (Gdansk Newsroom)
 ((gdansk.newsroom@thomsonreuters.com; +48 58 778 51 10;))